The proportion of aggressive prostate cancer in BRCA1 carriers was the same as in BRCA2 carriers (86.7%), which was higher than in noncarriers (61.1%) (odds ratio [OR] = 4.87; 95% confidence interval [CI] = 1.05 to 22.60; P = .043). This evidence concerns the gene BRCA2 and prostate carcinoma.